Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v7, Unresectable Renal Cell Carcinoma
Conditions
Brief summary
This randomized phase II trial studies how well pazopanib hydrochloride with or without ascorbic acid work in treating patients with kidney cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ascorbic acid may help pazopanib hydrochloride stop tumor growth and improve treatment survival. Giving pazopanib hydrochloride and ascorbic acid may work better in treating patients with kidney cancer.
Detailed description
PRIMARY OBJECTIVES: I. To estimate and compare treatment failure-free rate at 40 weeks from randomization of patients with unresectable/metastatic clear cell renal cell carcinoma (ccRCC) receiving one of the following regimens: Arm A: pazopanib hydrochloride (pazopanib) 800 mg daily plus intravenous (IV) ascorbic acid 1g/kg 3 times/week and Arm B: pazopanib 800 mg daily. SECONDARY OBJECTIVES: I. To estimate and compare the overall survival (OS) in patients receiving pazopanib with or without IV ascorbic acid. II. To estimate and compare the progression-free survival (PFS) in patients receiving pazopanib with or without IV ascorbic acid. III. To estimate and compare the overall response rate (ORR) in patients receiving pazopanib with or without IV ascorbic acid. IV. To estimate and compare the duration on pazopanib treatment in patients receiving pazopanib with or without IV ascorbic acid. V. To assess the adverse events (AE) profile and safety of each treatment arm using the Common Terminology Criteria for Adverse Events (CTCAE). CORRELATIVE RESEARCH: I. Correlation between 5 mC, 5 hmC and H3K27me3 expression (as determined by immunohistochemistry \[IHC\]), as well as MeDIP/hMeDIP sequencing (seq), and response to combination of IV ascorbic acid and pazopanib. II. Correlation between iron content in tumor microenvironment (as determined by Prussian blue staining) and response to combination of IV ascorbic acid and pazopanib combination. III. Correlation between HIF-1alpha and HIF-2alpha expression (as determined by immunohistochemistry \[IHC\]) and response to combination of IV ascorbic acid and pazopanib combination. IV. Correlation between GLUT1 expression (as determined by IHC) and response to combination of IV ascorbic acid and pazopanib. V. Correlation between PDL1 expression (as determined by IHC) and response to combination of IV ascorbic acid and pazopanib. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 8 weeks for up to 2 years.
Interventions
DRUGAscorbic Acid
Given IV
DRUGPazopanib Hydrochloride
Given PO
Sponsors
National Cancer Institute (NCI)
Academic and Community Cancer Research United
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological confirmation of clear cell renal cancer * Documented metastatic or unresectable disease and at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria; NOTE: Nephrectomy or ablation of the primary tumor is allowed prior to enrollment * No prior systemic therapy for clear cell renal cancer or have progressed after immunotherapy such as ipilimumab plus nivolumab in the first line; other immunotherapies (e.g. interleukin-2) or additional lines of immunotherapy may be allowed after discussion with the principal investigator * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (obtained =\< 21 days prior to registration) * Platelet (PLT) \>= 100,000/mm\^3 (obtained =\< 21 days prior to registration) * Hemoglobin (Hgb) \>= 9.0 g/dL (obtained =\< 21 days prior to registration); NOTE: Subjects may not have had a transfusion =\< 7 days of registration * Total Bilirubin =\< 1.5 x upper limit of normal (ULN) (obtained =\< 21 days prior to registration) * NOTE: For bilirubin elevation 1 to 1.5 x ULN, alanine aminotransferase (ALT) above 1.5 x ULN (upper limit of normal) is not permitted * NOTE: For bilirubin elevation 1 to 1.5 x ULN, aspartate aminotransferase (AST) above 1.5 x ULN (upper limit of normal) is not permitted * Alanine amino transferase (ALT) \< 2.5 X ULN, with normal bilirubin (obtained =\< 21 days prior to registration); NOTE: Concomitant elevations in bilirubin and ALT above 1.5 x ULN (upper limit of normal) is not permitted * Aspartate aminotransferase (AST) \< 2.5 X ULN, with normal bilirubin (obtained =\< 21 days prior to registration); NOTE: Concomitant elevations in bilirubin and AST above 1.5 x ULN (upper limit of normal) is not permitted * Creatinine =\< 1.5 mg/dl OR creatinine \> 1.5 mg/dl, estimated creatinine clearance must be \>= 55 mL/minute by Cockcroft Gault formula (obtained =\< 21 days prior to registration) * International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =\< 1.5 x ULN (obtained =\< 21 days prior to registration); NOTE: This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose * Individuals of non-childbearing potential, or individual of childbearing potential with negative serum pregnancy test =\< 7 days prior to randomization and willing to practice total abstinence or use a highly effective method of contraception, as outlined below: * Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female individual who has had the following: * A hysterectomy * A bilateral oophorectomy (ovariectomy) * A bilateral tubal ligation * Is post-menopausal * NOTE: Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses for \>= 1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value \> 40 mIU/mL and an estradiol value \< 40 pg/mL (\< 140 pmol/L); subjects using HRT must have experienced total cessation of menses for \>= 1 year and be greater than 45 years of age OR have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT * Childbearing potential, including any individual who has had a negative serum pregnancy test, =\< 7 days prior to randomization * Agrees to use adequate contraception; acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows: * Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product * Oral contraceptive, either combined or progestogen alone * Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year * Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject * Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository) * Provide informed written consent * Willing to provide archive tissue samples for correlative research purposes
Exclusion criteria
* Any of the following: * Individuals/or persons who are nursing * Individual/or persons who are pregnant * Individuals/or persons of childbearing potential who are unwilling to employ adequate contraception * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive * Prior history of receiving pazopanib or any other tyrosine kinase inhibitor treatments for malignancy * Uncontrolled intercurrent illness including, but not limited to: * Chronic ongoing or active infection * Symptomatic anemia * Uncontrolled hypertension (defined as systolic blood pressure \[SBP\] of \>= 160 mmHg or diastolic blood pressure \[DBP\] of \>= 100 mmHg) * Symptomatic congestive heart failure as defined by the New York Heart Association (NYHA) (does not exclude class III congestive heart failure \[CHF\]) * Unstable angina pectoris * Cardiac arrhythmia * Evidence of active bleeding or bleeding diathesis * Psychiatric illness/social situations that would limit compliance with study requirements * Any other serious uncontrolled medical disorders in the opinion of the investigator * History of a major thromboembolic event =\< 6 months prior to randomization, including cerebrovascular accident, transient ischemic attack (TIA), myocardial infarction, symptomatic pulmonary embolism (PE) or untreated deep venous thrombosis (DVT), or coronary artery bypass graft surgery; NOTE: Subjects with recent DVT or asymptomatic PE who have been treated with therapeutic anticoagulating agents for at least 6 weeks are eligible * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Other active malignancy =\< 5 years prior to randomization; EXCEPTIONS: Nonmelanoma skin cancer or carcinoma-in-situ of the cervix, or cancers with low metastatic potential (e.g. Gleason score 6 prostate cancer) treated with curative therapy; NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer * History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for =\< 6 months prior to randomization; Note: Screening with CNS imaging studies (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) is required only if clinically indicated or if the subject has a history of CNS metastases * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: * Active peptic ulcer disease * Known intraluminal metastatic lesion/s with risk of bleeding * Inflammatory bowel disease (e.g. ulcerative colitis, Crohn?s disease), or other gastrointestinal conditions with increased risk of perforation * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess =\< 28 days prior to randomization * Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: * Malabsorption syndrome * Any prior major resection of the stomach or small bowel * Corrected QT interval (QTc) \> 480 msecs using Bazett?s formula * Receiving any medications or substances with risk of Torsades de Pointes; Note: medications or substances on the list ?Drugs with Risk of Torsades de Pointes? are prohibited; medications or substances on the list ?Drugs with Possible or Conditional Risk of Torsades de Pointes? may be used while on study with extreme caution and careful monitoring * Treatment with any of the following anti-cancer therapies =\< 14 days prior to registration: * Radiation therapy * Surgery or tumor embolization * Chemotherapy, immunotherapy * Biologic therapy * Investigational therapy * Hormonal therapy * Prior autologous or allogeneic organ or tissue transplantation * Elective or planned major surgery to be performed during the course of the trial * Receiving any medications or substances that are strong or moderate inhibitors of CYP3A4; use of strong or moderate inhibitors are prohibited =\< 7 days prior to randomization * Receiving any medications or substances that are inducers of CYP3A4; use of inducers are prohibited =\< 7 days prior to randomization * Glucose-6-phosphate dehydrogenase (G6PD) deficiency (i.e. below normal limits) * End-stage renal disease (estimated glomerular filtration rate \[GFR\] \< 55 ml/min/body surface area \[BSA\]), unless the estimated creatinine clearance by Cockcroft Gault is \>= 55 ml/min prior to randomization * History of calcium oxalate stones * History of iron overload * Unable to swallow oral medications * History of myocardial infarction =\< 6 months, current symptomatic CHF or left ventricular ejection fraction (LVEF) \< 40% or \> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Failure-free Rate | At 40 weeks | Treatment failure is defined as any of the following: radiographic disease progression, off-protocol treatment due to adverse event, initiation of alternative therapy (except metastasectomy post clinical benefit (complete response \[CR\], partial response \[PR\], or stable disease \[SD\] per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 to treatment), and death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 26 months | Will be estimated using the method of Kaplan-Meier and be compared using log rank tests. |
| Progression Free Survival | 16 Months | Will be estimated using the Kaplan-Meier method. |
| Overall Response Rate | 16 Months | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scan, PET/CT, or MRI: Complete Response (CR), Disappearance of all target lesions and all target lymph nodes must have reduction in short axis to \<1.0 cm; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation; Overall Response (OR) = CR + PR. Will be compared using a Chi-Square test. |
| Duration of Time on Pazopanib Hydrochloride | 10 months | Will be described as the median time on treatment by arm. |
| Frequency of Adverse Events | 10 Months | Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Adverse events and toxicities will be evaluated using all patients who have received any study treatment as well as summarizing those who have been included in the efficacy analyses. The overall adverse event frequencies for grade 3 or higher adverse events, will be compared using Chi-Square tests between the 2 treatment arms. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm A (Pazopanib Hydrochloride, Ascorbic Acid) Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity. | 1 |
| Arm B (Pazopanib Hydrochloride) Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity. | 3 |
| Total | 4 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Did not meet inclusion criteria | 1 | 0 |
Baseline characteristics
| Characteristic | Arm A (Pazopanib Hydrochloride, Ascorbic Acid) | Arm B (Pazopanib Hydrochloride) | Total |
|---|---|---|---|
| Age, Continuous | 55 years | 56.7 years | 56.3 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 3 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| MSKCC Risk Factor Favorable risk | 0 Participants | 1 Participants | 1 Participants |
| MSKCC Risk Factor Intermediate risk | 0 Participants | 1 Participants | 1 Participants |
| MSKCC Risk Factor Poor risk | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 3 Participants | 4 Participants |
| Sex: Female, Male Female | 0 Participants | 1 Participants | 1 Participants |
| Sex: Female, Male Male | 1 Participants | 2 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 1 | 0 / 3 |
| other Total, other adverse events | 1 / 1 | 3 / 3 |
| serious Total, serious adverse events | 1 / 1 | 1 / 3 |
Outcome results
Primary
Treatment Failure-free Rate
Treatment failure is defined as any of the following: radiographic disease progression, off-protocol treatment due to adverse event, initiation of alternative therapy (except metastasectomy post clinical benefit (complete response \[CR\], partial response \[PR\], or stable disease \[SD\] per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 to treatment), and death due to any cause.
Time frame: At 40 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A (Pazopanib Hydrochloride, Ascorbic Acid) | Treatment Failure-free Rate | 0 Participants |
| Arm B (Pazopanib Hydrochloride) | Treatment Failure-free Rate | 2 Participants |
p-value: 1Fisher Exact
Secondary
Duration of Time on Pazopanib Hydrochloride
Will be described as the median time on treatment by arm.
Time frame: 10 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Pazopanib Hydrochloride, Ascorbic Acid) | Duration of Time on Pazopanib Hydrochloride | 5.9 Months |
| Arm B (Pazopanib Hydrochloride) | Duration of Time on Pazopanib Hydrochloride | 9.2 Months |
p-value: 0.18Kruskal-Wallis
Secondary
Frequency of Adverse Events
Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Adverse events and toxicities will be evaluated using all patients who have received any study treatment as well as summarizing those who have been included in the efficacy analyses. The overall adverse event frequencies for grade 3 or higher adverse events, will be compared using Chi-Square tests between the 2 treatment arms.
Time frame: 10 Months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A (Pazopanib Hydrochloride, Ascorbic Acid) | Frequency of Adverse Events | 1 Participants |
| Arm B (Pazopanib Hydrochloride) | Frequency of Adverse Events | 2 Participants |
p-value: 1Fisher Exact
Secondary
Overall Response Rate
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scan, PET/CT, or MRI: Complete Response (CR), Disappearance of all target lesions and all target lymph nodes must have reduction in short axis to \<1.0 cm; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation; Overall Response (OR) = CR + PR. Will be compared using a Chi-Square test.
Time frame: 16 Months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm A (Pazopanib Hydrochloride, Ascorbic Acid) | Overall Response Rate | 0 Participants |
| Arm B (Pazopanib Hydrochloride) | Overall Response Rate | 1 Participants |
p-value: 1Fisher Exact
Secondary
Overall Survival
Will be estimated using the method of Kaplan-Meier and be compared using log rank tests.
Time frame: 26 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Pazopanib Hydrochloride, Ascorbic Acid) | Overall Survival | 7.8 Months |
| Arm B (Pazopanib Hydrochloride) | Overall Survival | NA Months |
p-value: 0.08Log Rank
Secondary
Progression Free Survival
Will be estimated using the Kaplan-Meier method.
Time frame: 16 Months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A (Pazopanib Hydrochloride, Ascorbic Acid) | Progression Free Survival | 5.7 Months |
| Arm B (Pazopanib Hydrochloride) | Progression Free Survival | 11.8 Months |
p-value: 0.08Log Rank